Skip to main content

Advertisement

SpringerLink
Log in

Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C

Comparison between Interferon-α-2a and Interferon-α-2b

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background and objective: Interferon-α treatment is associated with a large number of adverse effects. Depressive symptoms are not unexpected, and potentially dangerous psychiatric adverse effects can induce life-threatening conditions. We compared the incidence of depressive symptoms in patients with chronic hepatitis C during treatment with pegylated interferon-α-2a (IFNα-2a) and pegylated interferon-α-2b (IFNα-2b).

Patients and design: We randomly divided 186 subjects with chronic hepatitis C into two treatment groups: group A, treated with IFNα-2a, and group B, treated with IFNα-2b. Treatment was continued for up to 48 weeks. Liver biopsy and hepatitis C virus RNA assay were carried out in all patients. Depressive symptoms and the prevalence of psychiatric adverse effects during treatment with IFN were evaluated using the Hamilton Depression Rating Scale, the Zung Self-Rating Depression Scale, and the Structured Clinical Interview for Diagnostic and Statistic Manual-IV axis disorders.

Results: At baseline 53% of subjects in group A and 57% of subjects in group B presented with depressive symptoms; at 12 weeks we found a high incidence of depressive symptoms in both groups (group A 61% and group B 65%) and three cases of life-threatening psychiatric symptoms (i.e. psychosis and delirium requiring discontinuation of antiviral therapy and admission to a psychiatric unit) in group A.

Conclusions: Long-term administration of IFN can be associated with serious psychiatric adverse effects. It is very important that psychiatric symptoms are diagnosed early in IFN treatment so to improve treatment compliance and prevent fatal and/or life-threatening adverse events, as were documented in some subjects treated with IFNα-2a in our study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Foster GR. Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825–30

    Article  PubMed  CAS  Google Scholar 

  2. First Annual meeting of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 2006; 1: S56-9

    Google Scholar 

  3. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha Interferon. J Hepatol 1996; 24: 38–47

    Article  PubMed  CAS  Google Scholar 

  4. Scalori A, Pozzi M, Bellia V, et al. Interferon-induced depression: prevalence and management. Dig Liver Dis 2005; 37: 102–7

    Article  PubMed  CAS  Google Scholar 

  5. Bonaccorso S, Marino V, Biondi M, et al. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002; 72: 237–41

    Article  PubMed  CAS  Google Scholar 

  6. Dieperink E, Ho SB, Tetrick L, et al. Suicidal ideation during interferon-alpha 2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych 2004; 26: 237–40

    Article  Google Scholar 

  7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 4315

    Article  Google Scholar 

  8. DSM IV-TR: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Arlington (VA): American Psychiatric Association, 2000

  9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62

    Article  PubMed  CAS  Google Scholar 

  10. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63–70

    Article  PubMed  CAS  Google Scholar 

  11. Steinberg M. Structured Clinical Interview for DSM-IV axis disorders. Arlington (VA): American Psychiatric Association, 1994

    Google Scholar 

  12. Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychology 1998; 37: 93–7

    CAS  Google Scholar 

  13. Diepering E, Willebring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157: 867–76

    Article  Google Scholar 

  14. Madday WC. Safety of combination interferon alpha-2b/ribavirin therapy on chronic hepatitis C-relapsed and treatment-naïve patients. Semin Liver Dis 1999; 19Suppl. 1: 67–75

    Google Scholar 

  15. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25–46

    Article  PubMed  CAS  Google Scholar 

  16. Loftis JM, Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004; 82: 175–90

    Article  PubMed  CAS  Google Scholar 

  17. Juengling FD, Ebert D, Gut O, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383–9

    Article  CAS  Google Scholar 

  18. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002; 347: 975–82

    Article  PubMed  CAS  Google Scholar 

  19. Manns MP, McHutchison JG, Gordon SC, et al. Pegintron alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65

    Article  PubMed  CAS  Google Scholar 

  20. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Pegintron alpha 2-a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 436–55

    Google Scholar 

  21. Zeuzem S, Diago M, Gane E, et al. Peginterferon alpha-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724–32

    Article  PubMed  CAS  Google Scholar 

  22. Kraus MR, Schafer A, Faller H, et al. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alpha-2b therapy. Psychiatry 2003; 64: 708–14

    Google Scholar 

  23. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C. Hepatology 2002; 36Suppl. 5: S1–2

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy

    Sergio Neri, Davide Pulvirenti & Gaetano Bertino

Authors
  1. Sergio Neri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Davide Pulvirenti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gaetano Bertino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergio Neri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neri, S., Pulvirenti, D. & Bertino, G. Psychiatric Symptoms Induced by Antiviral Therapy in Chronic Hepatitis C. Clin. Drug Investig. 26, 655–662 (2006). https://doi.org/10.2165/00044011-200626110-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200626110-00005

Keywords

Search

Navigation